Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 14/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709374 | 0.86 | VDR (0.40) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709375 | 0.85 | VDR (0.41) | VDRHDAC3HDAC6AR | |
| SCHEMBL2971486 | 0.84 | VDR (0.50) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709404 | 0.84 | VDR (0.40) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709379 | 0.83 | VDR (0.40) | VDRHDAC3HDAC6AR | |
| SCHEMBL14086434 | 0.83 | VDR (0.41) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709328 | 0.82 | VDR (0.43) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709369 | 0.81 | HDAC6 (0.57) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709326 | 0.81 | VDR (0.43) | VDRHDAC3HDAC6AR | |
| SCHEMBL13709373 | 0.80 | VDR (0.39) | VDRHDAC3HDAC6AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885HDAC3 1756/4885HDAC6 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.